Abbott and MSD Pharmaceuticals have entered into a distribution agreement for MSD’s oral anti-diabetic medicine sitagliptin, its combination sitagliptin/ metformin and the extended-release version in India. Abbott will distribute the portfolio in the country. The products are marketed under brand names Januvia, Janumet and Janumet XR, the companies said in a joint statement. Sitagliptin is a Dipeptidyl Peptidase IV Inhibitor used for treatment of Type-2 diabetes. It was discovered and developed by MSD Pharmaceuticals and the first DPP4i was launched in India in 2008. The brands under this portfolio continue to be among the leaders in the category, even after loss of exclusivity, they said.
The US Food and Drug Administration (FDA) has issued two observations to the oncology injectable plant of Zydus in Ahmedabad. The observations were issued following a GMP follow-up inspection of the facility in SEZ 1, near Matoda from June 9-18. They were not related to data integrity. The company will closely work with the US FDA to address and respond to the observations in an expeditious manner, Zydus said on Wednesday.
- Also read: Indosolar to relist as WaareeIndo
Welcure Drugs & Pharmaceuticals on Wednesday said it has executed a definitive mandate for third-party sourcing and procurement services aggregating to ₹517 crore with Thailand-based Fortune Sagar Impex Company. Welcure Drugs & Pharmaceuticals Ltd will engage in sourcing and procurement of multiple finished-dosage SKUs, the company said in an exchange filing. Built on a fee-based model, the company will earn a fixed 5 per cent commission on the cost of goods, the filing stated.
- Also read: Negative bias seen for Nifty, Sensex at open